Inovio Pharmaceuticals Securities Fraud Lawsuit
Analysis based on 17 articles · First reported Feb 12, 2026 · Last updated Feb 19, 2026
The market is negatively impacted by the news of Inovio Pharmaceuticals' alleged securities fraud, leading to a significant drop in its stock price. This event highlights regulatory risks and potential legal liabilities for biotechnology companies, potentially increasing investor scrutiny in the sector.
Inovio Pharmaceuticals is facing a securities fraud class action lawsuit initiated by the Law Offices of Howard G. Smith. The lawsuit alleges that Inovio Pharmaceuticals made materially false and misleading statements to investors regarding its recurrent respiratory papillomatosis (RPR) treatment, INO-3107, and its CELLECTRA device. Specifically, Inovio Pharmaceuticals allegedly failed to disclose manufacturing deficiencies with CELLECTRA, which led to delays in submitting the Biologics License Application (BLA) for INO-3107 to the United States===Food and Drug Administration (FDA). Furthermore, the company's claims of eligibility for accelerated FDA approval were reportedly unfounded, as the FDA accepted the BLA on a standard review timeline. These disclosures caused Inovio Pharmaceuticals' stock price to fall significantly, injuring investors who purchased securities between October 10, 2023, and December 26, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard